Muscle atrophy associated with glucagon-like Peptide-1 receptor agonists: A population-based observational study - PubMed
5 hours ago
- #GLP-1 receptor agonists
- #Pharmacovigilance
- #Muscle atrophy
- GLP-1 receptor agonists (GLP-1 RAs) may contribute to muscle atrophy, as suggested by a population-based observational study.
- The study analyzed FDA Adverse Event Reporting System (FAERS) data from 2003 to 2024, identifying 142 cases of muscle atrophy linked to GLP-1 RA therapy.
- Semaglutide and tirzepatide showed significant disproportionality in muscle atrophy reports (ROR = 2.39 and 1.69, respectively), while exenatide and liraglutide had lower reporting odds.
- The findings indicate a pharmacovigilance signal for muscle atrophy with certain GLP-1 RAs, but do not establish causality.
- Future studies should include objective measures of muscle mass and function to further investigate these associations.